Oncobiologics (ONS) Stock Price, News & Analysis

Company Overview

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Key Stats

• Today's Range: $2.14 to $2.31
• 50-Day Range: $0.72 to $7.40
• 52-Week Range: $0.57 to $1.53
• Volume: 1.07 million shs
• Average Volume: 69,024 shs
• Market Capitalization: $165.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ONS Stock Analysis - Frequently Asked Questions

When did Oncobiologics IPO?

Oncobiologics (ONS) raised $35 million in an IPO on Friday, May 13th 2016. The company issued 5,800,000 shares at a price of $6.00 per share. Jefferies and Barclays acted as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

What other stocks do shareholders of Oncobiologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include CRISPR Therapeutics (CRSP), Network-1 Technologies (NTIP), Allena Pharmaceuticals (ALNA), Intra-Cellular Therapies (ITCI), Cidara Therapeutics (CDTX), Neuralstem (CUR) and Exelixis (EXEL).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ONS
• Previous Symbol: NYSE:ONS
• CUSIP: N/A
• CIK: 1649989
• Web: www.oncobiologics.com
• Phone: (609) 619-3990
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-38,840,000.00
• Net Margins: -464.47%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -93.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.41
• Quick Ratio: 0.41

Sales & Book Value

• Annual Sales: $3.81 million
• Price / Sales: 43.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.36) per share
• Price / Book: -1.69

Miscellaneous

• Outstanding Shares: 72,200,000
• Free Float: N/A
• Market Cap: $165.70 million
• Optionable: Not Optionable
• Beta: -0.27